Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Holding KRON?
Track your performance easily
KRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.69 - $1.60
Previous Close$0.94
Volume213.57K
Average Volume (3M)163.32K
Market Cap
$56.85M
Enterprise Value-$52.66M
Total Cash (Recent Filing)$136.65M
Total Debt (Recent Filing)$27.13M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 05, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding60,294,610
10 Day Avg. Volume63,963
30 Day Avg. Volume163,316
Standard Deviation0.20
R-Squared0.20
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)6.82
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.26
Enterprise Value/Gross Profit-8.38
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$4.13Price Target Upside348.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Kronos Bio News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentKB-0742 demonstrated a DCR of 48% in the two highest dose cohorts with dose-dependent clinical activity, and 1 PR lasting 113 days was achieved in a 7th line myxoid liposarcoma (ML) patient.
Financial PerformanceKronos ended 2Q24 with $136.6M in cash, cash equivalents, and marketable securities, providing an operational runway.
Research And DevelopmentManagement believes there is still a high level of unmet need in multiple myeloma, and that p300 is a promising target, especially for the refractory population as a monotherapy or in combination.
Bears Say
Clinical DataNo complete responses or CRs with partial hematologic recovery (CRhs) were observed in any of the 24 evaluable patients in the lanra trial.
Clinical TrialsKronos has decided to not move lanra forward into the Phase II portion of the Phase I/II trial of lanraplenib (lanra) + Xospata (gilteritinib) in r/r FLT3-mut AML.
Regulatory ApprovalRisks include inability to obtain regulatory approval for KB-0742.
---
Ownership Overview
57.22% Insiders
13.66% Mutual Funds
21.07% Other Institutional Investors
8.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.69 and its highest was $1.60 in the past 12 months.
What is Kronos Bio’s market cap?
Currently, no data Available
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Kronos Bio’s earnings last quarter?
Kronos Bio released its earnings results on Aug 08, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.065.
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Undervalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate is -$0.28.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,294,610 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Kronos Bio reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -7.207%.
Which hedge fund is a major shareholder of Kronos Bio?
Among the largest hedge funds holding Kronos Bio’s share is Wildcat Capital Management, Llc. It holds Kronos Bio’s shares valued at 2M.
---
Kronos Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (348.86% Upside)
$4.13 (348.86% Upside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 955.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $730.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.41%
12-Months-Change
Fundamentals
Return on Equity
-63.01%
Trailing 12-Months
Asset Growth
-36.97%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Month Forecast
Average Price Target
$4.13
▲(348.86% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
Mersana Therapeutics
―
Oncternal Therapeutics
―
Best Analysts Covering KRON
1 Year
1 Year Success Rate
1/17 ratings generated profit
1 Year Average Return
-39.26%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -39.26% per trade.
---